Please use this identifier to cite or link to this item:
|Title:||Hepatic encephalopathy associated with cancer or anticancer therapy|
|Citation:||Gastrointestinal cancer research : GCR, 2013; 6(1):11-16|
|Publisher:||International Society of Gastrointestinal Oncology|
|Kaspar J. Willson, Louise M. Nott, Vy T. Broadbridge, Timothy Price|
|Abstract:||Hepatic encephalopathy is an uncommon cause of neurologic deterioration associated with hyperammonemia, which results from hepatic dysfunction or altered ammonia metabolism. Often overlooked, hyperammonemia may occur via any of several pathophysiological processes, and in the setting of malignancy, it is a potentially reversible cause of confusion and coma. Hepatic dysfunction as a result of malignant infiltration, chemotherapeutic toxicities, targeted anticancer therapies, reactivation hepatitis, portosystemic shunting, and transarterial chemoembolization (TACE) is discussed, and an approach to etiological diagnosis and management is outlined.|
|Rights:||© 2013 by International Society of Gastrointestinal Oncology|
|Appears in Collections:||Aurora harvest 4|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.